Christophe Sajous

520 total citations
21 papers, 275 citations indexed

About

Christophe Sajous is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Christophe Sajous has authored 21 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Christophe Sajous's work include Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christophe Sajous is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christophe Sajous collaborates with scholars based in France, Italy and Belarus. Christophe Sajous's co-authors include Julien Péron, Olivier Trédan, Christophe Caux, Thien‐Phong Vu Manh, Marc Dalod, Nathalie Bendriss‐Vermare, Janice Kielbassa, Isabelle Treilleux, Jenny Valladeau‐Guilemond and Anne‐Claire Doffin and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Christophe Sajous

20 papers receiving 270 citations

Peers

Christophe Sajous
Benjamin Bonhomme France
Tuan S. Nguyen United States
Christopher Dakhil United States
Fiona Nussey United Kingdom
Ying‐Yang Liao China
P. Nadella United States
Alison Lannigan United Kingdom
Jennifer McLachlan United Kingdom
Blessie Elizabeth Nelson United States
Shengwei Mo China
Benjamin Bonhomme France
Christophe Sajous
Citations per year, relative to Christophe Sajous Christophe Sajous (= 1×) peers Benjamin Bonhomme

Countries citing papers authored by Christophe Sajous

Since Specialization
Citations

This map shows the geographic impact of Christophe Sajous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Sajous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Sajous more than expected).

Fields of papers citing papers by Christophe Sajous

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Sajous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Sajous. The network helps show where Christophe Sajous may publish in the future.

Co-authorship network of co-authors of Christophe Sajous

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Sajous. A scholar is included among the top collaborators of Christophe Sajous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Sajous. Christophe Sajous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Decaussin‐Petrucci, Myriam, Françoise Descôtes, Gérald Raverot, et al.. (2025). From hyperplasia to carcinoma: a molecular driven adrenal disease. European Journal of Endocrinology. 192(6). K55–K59.
2.
Thibault, Constance, Loı̈c Mourey, Dominique Pasquier, et al.. (2025). OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.. Journal of Clinical Oncology. 43(5_suppl). 472–472. 1 indexed citations
3.
Corbaux, Pauline, Gilles Freyer, Olivier Gléhen, et al.. (2024). Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort. Clinical Cancer Research. 30(16). 3438–3446. 3 indexed citations
4.
Lasolle, Hélène, Livia Lamartina, Camille Buffet, et al.. (2024). Patients with medullary thyroid carcinoma and long term treatment with vandetanib: a study from the endocan -tuthyref network. Endocrine Abstracts. 1 indexed citations
5.
Barthélémy, Philippe, Yohann Loriot, Aude Fléchon, et al.. (2023). 2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM). Annals of Oncology. 34. S1211–S1212. 2 indexed citations
6.
Colomba, Émeline, Jérôme Alexandre, Gwénaël Le Teuff, et al.. (2022). Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. Gynecologic Oncology. 169. 78–84. 1 indexed citations
7.
Deandreis, Désirèe, Aline Maillard, Slimane Zerdoud, et al.. (2021). RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 48(10). 3238–3249. 8 indexed citations
8.
Freyer, Gilles, Anne Floquet, Olivier Trédan, et al.. (2021). 733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study. Annals of Oncology. 32. S734–S735. 6 indexed citations
9.
Péron, Julien, Anne Conrad, Fanny Pineau, et al.. (2021). COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study. Cancers. 13(21). 5283–5283. 10 indexed citations
10.
Sajous, Christophe, Sara Calattini, Marion Chauvenet, et al.. (2021). Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL). Cancers. 14(1). 29–29. 3 indexed citations
11.
Vano, Yann, Sylvain Ladoire, Réza Elaidi, et al.. (2021). First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. Cancers. 13(21). 5548–5548. 10 indexed citations
12.
Maillet, Denis, Nathalie Allioli, Julien Péron, et al.. (2021). Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers. 13(23). 6014–6014. 7 indexed citations
13.
14.
Hubert, Margaux, Élisa Gobbini, Coline Couillault, et al.. (2020). IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science Immunology. 5(46). 105 indexed citations
15.
Colomban, Olivier, Michel Tod, Julien Péron, et al.. (2020). Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum. 4(3). pkaa026–pkaa026. 23 indexed citations
16.
Sajous, Christophe, Simon Thézenas, Sophie Piperno‐Neumann, et al.. (2020). Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. Annals of Surgical Oncology. 27(6). 1818–1827. 29 indexed citations
17.
Sajous, Christophe, Julien Péron, Olivier Gléhen, et al.. (2020). Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. Cancers. 12(9). 2414–2414. 8 indexed citations
18.
Hubert, Margaux, Coline Couillault, Thien‐Phong Vu Manh, et al.. (2020). Abstract A70: IFN-III is selectively produced by cDC1 and predicts good clinical outcome in human breast cancer. Cancer Immunology Research. 8(4_Supplement). A70–A70. 1 indexed citations
19.
Sajous, Christophe, Simon Thézenas, Sophie Piperno‐Neumann, et al.. (2019). Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. Annals of Surgical Oncology. 27(5). 1693–1699. 13 indexed citations
20.
Kfoury, Maria, Cécile Vicier, Olivia Le Saux, et al.. (2018). Actualités autour des inhibiteurs de checkpoints immunitaires : enseignements issus du congrès ASCO 2017 et perspectives. Bulletin du Cancer. 105(7-8). 686–695. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benjamin Bonhomme Breakdown of academic impact, for papers by Tuan S. Nguyen Breakdown of academic impact, for papers by Christopher Dakhil Breakdown of academic impact, for papers by Fiona Nussey Breakdown of academic impact, for papers by Ying‐Yang Liao Breakdown of academic impact, for papers by P. Nadella Breakdown of academic impact, for papers by Alison Lannigan Breakdown of academic impact, for papers by Jennifer McLachlan Breakdown of academic impact, for papers by Blessie Elizabeth Nelson Breakdown of academic impact, for papers by Shengwei Mo
Rankless by CCL
2026